STOCK TITAN

If You Invested in Femasys Inc. (FEMY)

Healthcare · Medical Instruments & Supplies · NASDAQ
Looking for the current price? See the FEMY quote & overview
$1,000 invested 1 Year Ago
$76
-92.4% price return
-92.4% with dividends reinvested
Bought on Nov 19, 2025 at $15.18 split-adjusted
$1,000 invested 5 Years Ago
$11
-98.9% price return -59.1% CAGR
-98.9% with dividends reinvested
Bought on Nov 19, 2021 at $100.20 split-adjusted
$1,000 invested 10 Years Ago
N/A
Our prices start Jun 18, 2021

What $1,000 or $10,000 in FEMY Would Be Worth Now

Real historical value by amount invested and how long ago
If you invested 1 year ago 5 years ago 10 years ago Since Jun 18, 2021
$1,000 $76 -92% $11 -99% — $4.79 -99.52%
$10,000 $758 -92% $115 -99% — $48 -99.52%

Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-18. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.

Custom Calculation

Choose your own date and amount for FEMY

$1,000 Investment Over Time

FEMY vs S&P 500

Year-by-Year Returns

FEMY annual performance
Year Start Price End Price Annual Return Cumulative
2021Jun 18 to Dec 31 $240.00 $78.00 -67.5% -67.5%
2022 $78.00 $18.00 -76.9% -92.5%
2023 $18.00 $19.50 +8.3% -91.9%
2024 $19.50 $22.00 +12.8% -90.8%
2025 $22.00 $11.52 -47.6% -95.2%
2026Dec 31, 2025 to Nov 18 $11.52 $1.15 -90.0% -99.5%

About Femasys Inc.

Healthcare · NASDAQ

Femasys Inc. (NASDAQ: FEMY) is a biomedical company in the surgical and medical instrument manufacturing industry that focuses on women’s reproductive health. According to company disclosures, Femasys is a U.S. manufacturer with global regulatory approvals and is centered on making fertility treatment and non-surgical permanent birth control more accessible and cost-effective for women worldwide. The company develops and commercializes a patent-protected portfolio of in-office therapeutic and diagnostic products designed for use by clinicians in gynecology and reproductive medicine.

Business focus and product portfolio

Femasys describes itself as a biomedical innovator dedicated to fertility and permanent birth control. Its fertility portfolio includes FemaSeed Intratubal Insemination, characterized in company materials as a groundbreaking first-step infertility treatment, and FemVue, a companion diagnostic used for fallopian tube assessment via ultrasound. Published clinical trial data cited by the company indicate that FemaSeed has achieved pregnancy rates more than twice those of traditional intrauterine insemination (IUI) in cases involving low male sperm count, with a comparable safety profile and high patient and practitioner satisfaction.

In addition to fertility solutions, Femasys is advancing FemBloc permanent birth control, which it describes as the first and only non-surgical, in-office alternative to traditional surgical sterilization. Company announcements state that FemBloc received full regulatory approval in Europe in June 2025, in the United Kingdom in August 2025, and in New Zealand in September 2025. FemBloc uses a patented delivery system to place a proprietary blended polymer into both fallopian tubes, which then safely degrades and leads to natural scar tissue formation for permanent occlusion. Femasys positions FemBloc as a safer, more convenient and cost-effective option compared with surgical sterilization, noting that it does not require anesthesia, incisions or recovery time.

Alongside FemBloc, the company has developed FemChec, an ultrasound-based diagnostic product used to confirm the success of the FemBloc procedure. Femasys reports that initial clinical trials of FemBloc and FemChec have demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction. For the U.S. market, FemBloc remains a product candidate, with enrollment in the FINALE pivotal trial (NCT05977751) described as ongoing in company communications.

Diagnostic innovation and FemVue Controlled

Femasys also focuses on diagnostic devices that support fertility care. The company announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for FemVue Controlled, described as a next-generation diagnostic device designed for controlled delivery of a consistent alternating pattern of saline and air as contrast media during ultrasound imaging to evaluate fallopian tube status. FemVue Controlled integrates features of the original FemVue and FemChec technologies into a single FDA-cleared platform, enabling multiple clinical uses within one solution, including confirmation of tubal patency prior to use with FemaSeed. This integration is intended to streamline manufacturing and practice workflows by combining related diagnostic functions in one device.

Commercialization and geographic reach

According to repeated company descriptions, Femasys is actively commercializing its lead product innovations in the United States and key international markets. FemaSeed is authorized for use in the U.S., Europe, the UK, Canada and Israel, and in some disclosures also in Australia and New Zealand. The company has highlighted partnerships to broaden access to its products, such as a collaboration with Refuah Health Center to offer FemaSeed as a first step in the infertility treatment process within a community-based care setting. Femasys has also entered into distribution partnerships in Europe, including agreements with Kebomed to commercialize FemBloc permanent birth control in France and the Benelux region, and has reported initial commercial orders in Spain and France.

For FemBloc, Femasys has emphasized a European commercialization strategy supported by strategic partnerships in select countries. The company has also initiated a post-market surveillance clinical study for FemBloc in Europe under the European Union Medical Device Regulation (EU MDR 2017/745). This study is described as being conducted in accordance with ISO 14155:2020 for Good Clinical Practice and applicable national regulations, with the goal of monitoring safety and performance in real-world use and supporting broader physician adoption and reimbursement.

Regulatory and clinical development

Femasys’ disclosures highlight a regulatory and clinical pathway that combines commercial products and late-stage development candidates. FemaSeed and FemVue are described as commercially available fertility solutions with supporting clinical trial data. FemBloc is already approved in certain non-U.S. markets, while in the United States it remains under clinical investigation. The U.S. FDA granted Investigational Device Exemption (IDE) approval allowing Femasys to continue enrollment in the final phase (Part B) of the FINALE pivotal trial for FemBloc, following successful completion of Part A. The company characterizes this IDE approval as a critical step toward potential U.S. Pre-Market Approval (PMA) for FemBloc.

Femasys also notes that it operates under a broad, patent-protected portfolio, indicating a focus on intellectual property protection around its therapeutic and diagnostic technologies. Its regulatory filings describe the company as an emerging growth company and a smaller reporting company under U.S. securities regulations.

Capital markets and listing status

Femasys Inc. is incorporated in Delaware and its common stock, with a par value of $0.001 per share, is listed on The Nasdaq Capital Market under the trading symbol FEMY. The company has filed registration statements on Form S-1 and amendments related to offerings of common stock, pre-funded warrants and common warrants, as well as Form 8-K reports describing private placements of senior secured convertible notes and associated warrants. These financings are described as intended to refinance existing debt, support commercialization of the fertility and permanent birth control portfolio, and provide working capital.

Nasdaq has notified Femasys at various times regarding continued listing requirements. Company disclosures state that Femasys received a notice related to the Market Value of Listed Securities and other quantitative standards, and later reported that, on a pro forma basis after an underwritten offering and warrant exercises, it believed it met the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. In a separate notice, Femasys reported that Nasdaq granted the company an additional 180-calendar day extension to regain compliance with the minimum closing bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). During this extension period, the company’s common stock continues to trade on The Nasdaq Capital Market under the symbol FEMY, and Femasys has indicated that it may effect a reverse stock split, if necessary, to cure the deficiency.

Financial reporting and SEC filings

Femasys files periodic reports with the U.S. Securities and Exchange Commission (SEC), including Forms 10-Q and 10-K, as well as current reports on Form 8-K describing material events. In its Form 10-Q for the quarter ended September 30, 2025, summarized in an accompanying press release, the company reported sales growth compared with the prior-year period, attributing the increase primarily to sales of FemBloc and FemVue. The same report outlined research and development, sales and marketing, and general and administrative expenses, as well as net loss figures and information on cash, cash equivalents, inventory and other balance sheet items. Femasys has characterized itself as focused on advancing its women’s health portfolio while managing its capital position through financings and cost controls.

Industry context and positioning

Within the surgical and medical instrument manufacturing industry, Femasys concentrates on gynecologic and reproductive health technologies. Its products are designed for in-office use by clinicians, with an emphasis on minimally invasive approaches. Company communications consistently describe a mission to transform women’s healthcare by providing practical, clinician-focused innovations that can be delivered in office-based settings, with potential implications for patient access and health economics. By combining fertility treatments like FemaSeed with diagnostics such as FemVue and FemVue Controlled, and a non-surgical permanent birth control option in FemBloc, Femasys presents an integrated set of tools aimed at key decision points in reproductive care.

Market Cap
$9.6M
Current Price
$1.15
EPS (FY2025)
-$9.40
Revenue (FY2025)
$2.3M
View full FEMY overview

Frequently Asked Questions

Femasys Inc. investment returns

How much would $1,000 invested in Femasys Inc. be worth today?

If you invested $1,000 in Femasys Inc. (FEMY) 5 years ago on 2021-11-19, your investment would be worth $11 as of 2026-11-18, a -98.9% price return without dividends, growing at a compounded rate of -59.1% per year (CAGR).

Has Femasys Inc. outperformed the S&P 500?

Comparison data requires at least 10 years of trading history. Use the calculator above to compare FEMY performance over available time periods.

What is Femasys Inc.'s average annual return?

The compound annual growth rate (CAGR) of FEMY’s share price over the past 5 years is -59.1%, without dividends. Individual years vary a great deal, and FEMY’s best recent full year was 2024 (+12.8%) while the worst was 2022 (-76.9%).

For informational and educational purposes only, not investment advice.